12.01 USD
+0.97 (+8.79%)
11.88 USD
-0.13 (-1.08%)
ChartMill assigns a Buy % Consensus number of 82% to AGLE. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 17.85. This target is 48.63% above the current price.
- AGLE was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AGLE.
- In the previous month the buy percentage consensus was at a similar level.
- AGLE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-16 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023-07-25 | Stifel | Initiate | Buy |
| 2023-04-12 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2023-04-12 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-03-03 | HC Wainwright & Co. | Maintains | Neutral |
| 2022-10-28 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2022-08-09 | Wells Fargo | Maintains | Equal-Weight |
| 2022-06-03 | Needham | Downgrade | Buy -> Hold |
| 2022-06-03 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-05-06 | Needham | Maintains | Buy |
AEGLEA BIOTHERAPEUTICS INC / AGLE FAQ
What do analysts expect the price target to be for AEGLEA BIOTHERAPEUTICS INC (AGLE)?
9 analysts have analysed AGLE and the average price target is 17.85 USD. This implies a price increase of 48.63% is expected in the next year compared to the current price of 12.01.
Can you provide the consensus rating for AEGLEA BIOTHERAPEUTICS INC stock?
The consensus rating for AEGLEA BIOTHERAPEUTICS INC (AGLE) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.